{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T21:11:04Z","timestamp":1778101864216,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.reumae.2026.502105","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:21:23Z","timestamp":1777594883000},"page":"502105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systematic review and network meta-analysis of interventions for articular involvement in patients with systemic lupus erythematosus"],"prefix":"10.1016","volume":"22","author":[{"given":"Pedro Arbey","family":"Quevedo Mayorga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana Isabel","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebasti\u00e1n","family":"Giraldo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristhian Camilo","family":"Guzm\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier Mauricio","family":"Mora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jhon Jairo","family":"Tipasoca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio Daniel","family":"Montalvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reumae.2026.502105_bib0005","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/01.md.0000091181.93122.55","article-title":"Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients","volume":"82","author":"Cervera","year":"2003","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.reumae.2026.502105_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.md.0000104742.42401.e2","article-title":"The GLADEL Multinational Latin American Prospective Inception Cohort of 1,214 Patients With Systemic Lupus Erythematosus: Ethnic and Disease Heterogeneity Among \u00abHispanics\u00bb","volume":"83","author":"Pons-Estel","year":"2004","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.reumae.2026.502105_bib0015","first-page":"90","article-title":"Diagnosis and treatment of articular manifestations of systemic lupus Gerythematosus","volume":"28","author":"Frade-Sosa","year":"2021","journal-title":"Rev Colomb Reumatol."},{"key":"10.1016\/j.reumae.2026.502105_bib0020","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0104-4230(12)70234-8","article-title":"Jaccoud arthropathy in systemic lupus erythematosus: clinical and serological findings","volume":"58","author":"Skare","year":"2012","journal-title":"Rev Assoc Med Bras (1992)."},{"key":"10.1016\/j.reumae.2026.502105_bib0025","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/MD.0b013e3181632d18","article-title":"Jaccoud arthropathy in systemic lupus erythematosus: analysis of clinical characteristics and review of the literature","volume":"87","author":"Santiago","year":"2008","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.reumae.2026.502105_bib0030","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1177\/0961203317716319","article-title":"Musculoskeletal manifestations as determinants of quality of life impairment in patients with systemic lupus erythematosus","volume":"27","author":"Piga","year":"2018","journal-title":"Lupus."},{"key":"10.1016\/j.reumae.2026.502105_bib0035","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/annrheumdis-2018-213512","volume":"77","author":"Pons-Estel","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reumae.2026.502105_bib0040","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reumae.2026.502105_bib0045","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1756-185X.2011.01665.x","article-title":"Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus","volume":"15","author":"Islam","year":"2012","journal-title":"Int J Rheum Dis."},{"key":"10.1016\/j.reumae.2026.502105_bib0050","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1136\/annrheumdis-2017-eular.4238","article-title":"SAT0241 Early response to belimumab in sle-related joint involvement evaluated by ultrasonographic assessment","volume":"76","author":"Massaro","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"10.1016\/j.reumae.2026.502105_bib0055","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/697525","article-title":"Efficacy of abatacept for arthritis in patients with an overlap syndrome between rheumatoid arthritis and systemic lupus erythematosus","volume":"2013","author":"Ikeda","year":"2013","journal-title":"Clin Dev Immunol."},{"key":"10.1016\/j.reumae.2026.502105_bib0060","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.reumae.2026.502105_bib0065","unstructured":"NMA [Internet]. PRISMA statement [accessed 23 May 2024]. Available from: https:\/\/www.prisma-statement.org\/nma."},{"key":"10.1016\/j.reumae.2026.502105_bib0070","unstructured":"Search Help - CADTH Grey Matters - Canadian Agency for Drugs and Technologies in Health [Internet] [accessed 5 Oct 2024]. Available from: https:\/\/greymatters.cadth.ca\/help."},{"key":"10.1016\/j.reumae.2026.502105_bib0075","unstructured":"INFORMATION - Rayyan [Internet]. 2022 [accessed 30 May 2024]. Available from: https:\/\/www.rayyan.ai\/cite\/."},{"key":"10.1016\/j.reumae.2026.502105_bib0080","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0025-7753(05)72205-3","article-title":"Ensayos cl\u00ednicos aleatorizados (CONSORT)","volume":"125","author":"Cobos-Carb\u00f3","year":"2005","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.reumae.2026.502105_bib0085","unstructured":"CARE Checklist [Internet]. CARE Case Report Guidelines [accessed 30 May 2024]. Available from: https:\/\/www.care-statement.org\/checklist."},{"key":"10.1016\/j.reumae.2026.502105_bib0090","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.reumae.2026.502105_bib0095","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.reumae.2026.502105_bib0100","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.reumae.2026.502105_bib0105","first-page":"1275","article-title":"Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus","volume":"26","author":"Carneiro","year":"1999","journal-title":"J Rheumatol."},{"key":"10.1016\/j.reumae.2026.502105_bib0110","doi-asserted-by":"crossref","first-page":"e485","DOI":"10.1016\/S2665-9913(25)00022-0","article-title":"Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trial","volume":"7","author":"Strand","year":"2025","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.reumae.2026.502105_bib0115","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet."},{"key":"10.1016\/j.reumae.2026.502105_bib0120","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1002\/art.30613","article-title":"A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus","volume":"63","author":"Furie","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reumae.2026.502105_bib0125","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.reumae.2026.502105_bib0130","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2016-000163","article-title":"Off-label use of rituximab for systemic lupus erythematosus in Europe","volume":"3","author":"Ryd\u00e9n-Aulin","year":"2016","journal-title":"Lupus Sci Med."},{"key":"10.1016\/j.reumae.2026.502105_bib0135","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)","volume":"401","author":"Morand","year":"2023","journal-title":"Lancet."},{"key":"10.1016\/j.reumae.2026.502105_bib0140","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/0961203313519159","article-title":"Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy","volume":"23","author":"Sakthiswary","year":"2014","journal-title":"Lupus."}],"container-title":["Reumatolog\u00eda Cl\u00ednica (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574326000602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173574326000602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T20:17:50Z","timestamp":1778098670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173574326000602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2173574326000602"],"URL":"https:\/\/doi.org\/10.1016\/j.reumae.2026.502105","relation":{},"ISSN":["2173-5743"],"issn-type":[{"value":"2173-5743","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic review and network meta-analysis of interventions for articular involvement in patients with systemic lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"Reumatolog\u00eda Cl\u00ednica (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reumae.2026.502105","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.reuma.2026.502105","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Reumatolog\u00eda (SER), Colegio Mexicano de Reumatolog\u00eda (CMR) and Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"502105"}}